CD195抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using CD195 mouse mAb against L-02 (1) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD195 mouse mAb (green) and negative control (red).    

  
  

CD195. also known as CCR5. is a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family. It is primarily expressed on immune cells, including T lymphocytes, macrophages, and dendritic cells, and plays a key role in mediating cell migration and inflammatory responses by binding to chemokines such as CCL3. CCL4. and CCL5. CCR5 gained prominence due to its role as a co-receptor for HIV-1 entry into host cells, making it a critical target in HIV research and therapeutic development.

CD195 antibodies are immunological tools designed to detect or modulate CCR5 activity. They are widely used in flow cytometry, immunohistochemistry, and functional studies to characterize CCR5 expression patterns, track immune cell subsets, or block receptor-ligand interactions. Specific clones (e.g., 2D7/CCR5) recognize distinct epitopes, with some exhibiting neutralizing capabilities to inhibit HIV infection or inflammatory signaling. These antibodies have also contributed to understanding CCR5's involvement in autoimmune diseases, cancer metastasis, and transplant rejection.

Clinically, CCR5 antagonists like maraviroc (derived from antibody-guided research) are approved for HIV treatment. Additionally, CRISPR-based CCR5 gene editing has been explored for HIV cure strategies. Recent studies further link CCR5 to tumor microenvironment regulation, expanding its relevance in oncology. The Δ32 mutation, a natural CCR5 variant conferring HIV resistance, underscores its biological and therapeutic significance. CD195 antibodies remain pivotal in both basic research and translational efforts targeting immune dysregulation and infectious diseases.